Keto Diet and Brain Disease: A Roadmap for Research

The keto diet’s reputation has raced ahead of the evidence behind it. Most people follow it for weight loss, and that is where their interest ends. Scientists investigating brain disease, however, have noticed a different pattern.

A research group in Portugal examined whether the metabolic changes caused by keto could account for the diet repeatedly appearing in research on Alzheimer’s, Parkinson’s and similar conditions.

Their conclusion goes beyond a broad suggestion that the diet may help the brain. It begins with an issue that most people on a keto diet are unlikely to know about.

Keto diet and brain disease

The brain relies chiefly on glucose, the sugar obtained from carbohydrates. In a number of brain diseases, this energy pathway stops working. Neurons become unable to use glucose and effectively starve, even when sugar is available.

When carbohydrates are removed, the body moves to an alternative system. The liver converts fat into substances known as ketone bodies. These can bypass the brain’s impaired processes and supply energy directly.

The most active is beta-hydroxybutyrate, or BHB. Researchers at Portugal’s University of Coimbra combined dozens of experiments to examine how this change in fuel could protect neurons.

Ana Margarida Salgueiro and her co-authors described a sequence of effects extending far beyond energy production. Their review brings together previously scattered findings into a single framework.

What brain scans reveal

Ketone levels in the blood are normally extremely low in healthy people. During fasting or deep ketosis – when the body uses fat rather than sugar for fuel – they rise considerably. The brain can then obtain much of its energy from ketones.

This adjustment is not immediate, but once established, ketones can provide a substantial proportion of neurons’ energy requirements. Here, the question of brain energy becomes more tangible.

Scans of people with mild Alzheimer’s reveal lower glucose use in important brain areas. Their capacity to use ketone-based fuel, however, remains close to normal. The impairment appears to affect sugar use specifically, rather than energy production as a whole.

One clinical study described this as brain energy rescue – providing neurons with another fuel source to stabilise what glucose can no longer maintain. The Coimbra researchers regard this as one of the stronger lines of evidence, particularly in Alzheimer’s, where disrupted sugar metabolism occurs early.

Reducing inflammation

BHB does more than serve as fuel: it also acts as a cellular signal. It suppresses a protein complex that initiates inflammation, reducing molecules that maintain inflammation in brain tissue.

Persistent inflammation is a feature across these diseases, and reducing it seems to restrict harm. Animal models of Alzheimer’s have shown measurable changes.

Indicators of activated immune cells decline, while inflammatory signalling molecules decrease. In certain mice, the diet also appeared to restore communication between neurons associated with memory and learning.

Whether BHB produced that effect directly, or whether other metabolic changes contributed, remains uncertain. This ketone also increases a growth factor that supports neuron survival and the formation of new connections.

This combination of lower inflammation and greater cellular support explains why researchers see potential for Parkinson’s, Huntington’s and other conditions. At present, though, the most convincing evidence remains laboratory-based rather than clinical.

Cellular clean-up and gut signals

Brain cells depend on a recycling process to remove damaged components and the misfolded proteins that build up during disease. As these conditions progress, that system deteriorates.

Ketosis seems to reactivate it, allowing cells to remove harmful clumps before they build up.

Keto also alters gut bacteria, with effects that extend to the brain. In young, healthy mice, it shifted gut populations away from inflammatory strains and towards beneficial ones – alongside improved blood flow in the brain.

A separate study involving people with mild cognitive impairment identified comparable changes, together with markers associated with Alzheimer’s.

The gut evidence is less robust than the research on energy. The substances produced by these bacteria differed between studies. The connection appears genuine, but remains far from established.

Why caution is needed

Despite the encouraging biology, the evidence has a major limitation: most of it comes from animals rather than people. A mechanism that performs well in a laboratory mouse may not translate to someone with progressing disease.

The ketogenic diet is also hard to maintain. It is among the most demanding eating plans to follow, and its side effects can include constipation, insomnia and raised cholesterol.

Some longer-term studies have also linked it with an increased risk of heart disease and type 2 diabetes. Those drawbacks must be balanced against any potential benefit to the brain.

The researchers therefore do not describe keto as a treatment. Instead, they present it as a possible addition to existing therapies – a way to increase resilience and reduce symptoms, rather than cure disease.

The balance of risks and benefits will vary from one patient to another.

A research roadmap

Before this review, research connecting keto with brain disease was spread across hundreds of experiments, with each one examining a single mechanism. Salgueiro and her team’s contribution is to provide one overall map.

It illustrates how energy supply, inflammation, cellular recycling and gut signalling all meet at the same neurons. That overlap is the finding most worth focusing on.

A diet commonly adopted for weight loss affects almost every process that breaks down in the ageing brain – through chemistry centred on ketones. The case is strongest in early-stage Alzheimer’s, where glucose metabolism is first to fail.

The result is a shift in the research agenda. Doctors are not about to prescribe bacon and butter for dementia. Yet the review gives clinical teams a defined objective: test whether supplying the brain with an alternative fuel can slow decline in people, rather than only in mice. That is what the next generation of human trials must determine.